Table 3.
Ventilatory data, other ICU therapies and medications used
| Parameter | Patient (N = 32^) |
|---|---|
| Respiratory support: | |
| High Flow Nasal Cannula | 5 (15.6%) |
| Intermediate Flow Nasal Cannula | 4 (12.5%) |
| Invasive Mechanical Ventilation (IMV) | 23 (71.9%) |
| Characteristics of IMV: Median (IQR) | |
| Lowest pre-intubation PaO2/FiO2 ratio * | 101 (75.8–183.8) |
| FiO2 4 hrs after intubation – percentage of oxygen | 70 (50–80) |
| PEEP max – cmH2O | 16 (14–20) |
| Plateau pressure 4 hrs after intubation – cmH2O | 26 (23–30.5) |
| Positive Inspiratory Pressure max – cmH2O | 29 (28–35) |
| Static compliance 4 hrs after intubation – cmH2O ** | 44 (31–59) |
| Driving pressures – cmH2O | 12 (0–14) |
| ICU therapies: | |
| Intravenous vasopressors | 12/32 (36.3%) |
| Neuromuscular blockade | 9/23 (39.1%) |
| Intravenous pulmonary vasodilators | 8/23 (34.8%) |
| Prone positioning | 7/23 (30.4%) |
| Extracorporeal membrane oxygenation (ECMO) | 3/23 (13.0%) |
| Peri-intubation intravenous fluids | 15/23 (65.2%) |
| Medication details: | |
| Hydroxychloroquine | 19 (59.4%) |
| Lopinavir-Ritonavir | 5 (15.6%) |
| Remdesivir | 0 (0%) |
| Tocilizumab | 3 (9.38%) |
| Azithromycin | 19 (59.4%) |
| Systemic Glucocorticoids | 15 (46.9%) |
| Statins | 19 (59.4%) |
| Concurrent antibiotics | 26 (8.1%) |
| ACE-i/ARB prior to hospitalization or during hospitalization | 10 (31.3%) |
| Thromboprophylaxis | 32 (100%) |
^N = 32 unless specified, *data available for 28 patients; we estimated PaO2 from SpO2 in 4 patients who did not have preventilation arterial blood gas values available. **Data available for 11 out of 23 patients intubated. ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker